Goal 2: Reduce Human Disease

Submitted by (@jalees)

Balancing Risks and Benefits: How Do Clinical Guidelines in Cardiovascular Medicine Promote the Health of an Individual?

Much of the hopes for precision medicine (as outlined Dr. Dr. Collins) are based on deriving large amounts of genomic, proteomic, epigenomic and metabolomic data on large cohorts of patients. It will take decades to build these cohorts and even more time to analyze them and derive specific conclusions on how these will help individualize treatments. However, there is a pressing need for how to individualize contemporary ...more »

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@jsullivan)

Prevent the Development of COPD

What can be done to prevent the development of COPD in individuals at increased risk. Quitting smoking before the development of COPD can prevent COPD development. What can be done to prevent COPD for individuals with other identified ris factors

Voting

15 net votes
18 up votes
3 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@roy.wallen)

Early prediction of cardiovascular disease by primary-care assessment

Tools for early assessment of cardiovascular disease have become available but not adopted in primary-care settings. Increased arterial stiffness is a well-known marker for advanced cardiovascular disease (CVD) and has been shown to be an independent predictor of cardiovascular mortality. In addition, arterial pulse wave velocity (PWV) has been readily accepted as a measure of arterial stiffness. Despite significant ...more »

Voting

5 net votes
8 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@greg.martin)

Develop and validate a metric to address the full spectrum of patient-level comorbidities affecting critical illness

An individual metric to inform about the additive and not individual impact of comorbidities on critical illness and peri-operative mortality. For instance, we know the impact of COPD or MI or CKD on mortality after hemicolectomy, but not necessarily the additive impact of all three.

Voting

2 net votes
4 up votes
2 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@leonardo.brandao)

Understand the Impact of Thrombosis in Children with Cancer

CC: Despite the potential impact that venous thrombotic events (VTE) have on children with cancer, several unresolved issues remain. To date, we are yet to understand: - incidence/prevalence of VTE according to cancer type/staging - ideal imaging modalities to diagnose/follow VTE - thromboprophylaxis according to thrombosis risk stratification (development of VTE predictors) - efficacy/safety to anticoagulate children ...more »

Voting

30 net votes
38 up votes
8 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@serevill)

Does lowering circulating lipoprotein(a) levels influence cardiovascular outcomes?

A comprehensive research strategy and plan is needed to determine the most efficient, safe, cost-effective and widely applicable strategy to decrease circulating levels of lipoprotein(a) and to determine whether lowering circulating lipoprotein(a) levels will reduce the risk of developing cardiovascular disease such as a heart attack or a stroke as well as the progression of atherosclerosis or aortic stenosis.

Voting

235 net votes
297 up votes
62 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@david.goff)

Should clinical primary prevention of ASCVD be guided by subclincal disease or estimated risk?

Current approaches to guiding use of clinical primary prevention interventions, e.g., statins and aspirin, are based on treating patients who exceed a specific risk threshold. The performance of risk estimation is good, but not outstanding, and results from clinical and population studies continue to support the value of new biomarkers. Given the widespread use of preventive therapies, the lack of untreated cohorts is ...more »

Voting

-3 net votes
6 up votes
9 down votes
Active